747413-18-9 Usage
Description
1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]Piperazine is an organic compound characterized by a complex structure that features a piperazine ring, a boron-containing phenyl group, and a methyl group. Its unique composition, particularly the presence of boron, renders it a valuable ligand in the realms of organic synthesis and catalysis. Additionally, the piperazine moiety endows this compound with potential biological activities, such as antihistaminic and antipsychotic effects, making it a promising candidate for pharmaceutical research and development.
Uses
Used in Organic Synthesis:
1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]Piperazine is utilized as a ligand in organic synthesis, taking advantage of its boron-containing structure to facilitate various chemical reactions and improve the efficiency of synthesis processes.
Used in Catalysis:
In the field of catalysis, this compound serves as a ligand to enhance the activity and selectivity of catalysts, contributing to more effective and environmentally friendly chemical transformations.
Used in Pharmaceutical Research and Development:
1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]Piperazine is employed in pharmaceutical research as a starting material or intermediate for the development of new drugs, capitalizing on its potential antihistaminic and antipsychotic properties. Its unique structure allows for the exploration of novel therapeutic agents that could address unmet medical needs.
Used in Chemical Research:
As an interesting target for chemical research, 1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]Piperazine is used to study the properties and reactivity of boron-containing organic compounds, which can lead to advancements in material science and the discovery of new chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 747413-18-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,7,4,1 and 3 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 747413-18:
(8*7)+(7*4)+(6*7)+(5*4)+(4*1)+(3*3)+(2*1)+(1*8)=169
169 % 10 = 9
So 747413-18-9 is a valid CAS Registry Number.
747413-18-9Relevant articles and documents
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00567; 00569; 001367; 001368, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS
-
Page/Page column 51; 66, (2015/07/07)
New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.
Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis
Patel, Gautam,Karver, Caitlin E.,Behera, Ranjan,Guyett, Paul J.,Sullenberger, Catherine,Edwards, Peter,Roncal, Norma E.,Mensa-Wilmot, Kojo,Pollastri, Michael P.
supporting information, p. 3820 - 3832 (2013/06/27)
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b
